Dermatitis/Eczema – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of dermatitis / eczema comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis / eczema for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s dermatitis / eczema forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dermatitis / eczema over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts one dermatitis / eczema patient populations, as follows:
- Total12-month prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Dermatitis/Eczema - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of dermatitis)
- Total 12-month prevalent cases of dermatitis
- Risk / protective factors applied to disease forecast models
- Reference Materials
- Bibliography
- Glossary
- Abbreviation table
Soundharya M., Epidemiologist, Epidemiology. Prior to joining the company, she worked as a project coordinator at an NGO. She holds a master’s degree in public health with a specialization in epidemiology from the Manipal Academy of Higher Education. Her area of interest is chronic disease epidemiology, and real-world data analysis.
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.